These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 7986719

  • 21. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography.
    Burnouf T, Michalski C, Goudemand M, Huart JJ.
    Vox Sang; 1989; 57(4):225-32. PubMed ID: 2617959
    [Abstract] [Full Text] [Related]

  • 22. Assessment of thrombogenicity of prothrombin complex concentrates in a porcine model.
    Harrison J, Abildgaard C, Lazerson J, Culbertson R, Anderson G.
    Thromb Res; 1985 Apr 15; 38(2):173-88. PubMed ID: 4002204
    [Abstract] [Full Text] [Related]

  • 23. Heat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.
    Benny AG, Ockelford PA, Johns AS, Woodfield DG, Berry EW.
    N Z Med J; 1986 Jun 11; 99(803):408-9. PubMed ID: 3461352
    [Abstract] [Full Text] [Related]

  • 24. Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs.
    Littlewood JD, Dawes J, Smith JK, Feldman PA, Haddon ME, McQuillan TA, Foster PR, Ferguson J, Prowse CV.
    Br J Haematol; 1987 Apr 11; 65(4):463-8. PubMed ID: 3580303
    [Abstract] [Full Text] [Related]

  • 25. Combined factor IX and protein C deficiency in a child: thrombogenic effects of two factor IX concentrates.
    Negrier C, Vial J, Vinciguerra C, Berruyer M, Dechavanne M.
    Am J Hematol; 1995 Feb 11; 48(2):120-4. PubMed ID: 7847325
    [Abstract] [Full Text] [Related]

  • 26. Potential thrombogenicity of heat-treated prothrombin complex concentrates in Haemophilia B.
    Hampton KK, Makris M, Kitchen S, Preston FE.
    Blood Coagul Fibrinolysis; 1991 Oct 11; 2(5):637-41. PubMed ID: 1782333
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
    Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I.
    Thromb Haemost; 2007 Oct 11; 98(4):790-7. PubMed ID: 17938803
    [Abstract] [Full Text] [Related]

  • 28. Coagulation factor IX: successful surgical experience with a purified factor IX concentrate.
    Goldsmith JC, Kasper CK, Blatt PM, Gomperts ED, Kessler CM, Thompson AR, Herring SW, Novak PL.
    Am J Hematol; 1992 Jul 11; 40(3):210-5. PubMed ID: 1609775
    [Abstract] [Full Text] [Related]

  • 29. In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. The influence of reagents and standards.
    Köhler M, Seifried E, Hellstern P, Pindur G, Miyashita C, Mörsdorf S, Fasco F, Wenzel E.
    Blut; 1988 Dec 11; 57(6):341-5. PubMed ID: 3207891
    [Abstract] [Full Text] [Related]

  • 30. Characteristics and thrombogenicity of factor IX concentrate.
    Sakuragawa N, Takahashi K, Itoh M, Matsuoka M.
    Bibl Haematol; 1977 Dec 11; 44():88-93. PubMed ID: 617788
    [Abstract] [Full Text] [Related]

  • 31. Increased thrombin generation in a child with a combined factor IX and protein C deficiency.
    Negrier C, Berruyer M, Durin A, Philippe N, Dechavanne M.
    Blood; 1993 Feb 01; 81(3):690-5. PubMed ID: 8427961
    [Abstract] [Full Text] [Related]

  • 32. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
    Lissitchkov T, Matysiak M, Zavilska K, Laguna P, Gercheva L, Antonov A, Moret A, Caunedo P, Aznar JA, Woodward MK, Páez A.
    Haemophilia; 2013 Sep 01; 19(5):674-8. PubMed ID: 23647607
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Preliminary in vivo evaluation of a nanofiltered factor IX concentrate.
    Mannucci PM, Tradati F.
    Thromb Haemost; 1995 Apr 01; 73(4):737-8. PubMed ID: 7495096
    [No Abstract] [Full Text] [Related]

  • 36. In vitro spontaneous thrombin generation in human factor-IX concentrates.
    Sas G, Owens RE, Smith JK, Middleton S, Cash JD.
    Br J Haematol; 1975 Sep 01; 31(1):25-35. PubMed ID: 1212434
    [Abstract] [Full Text] [Related]

  • 37. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
    Serban M, Skotnicki AB, Colovic M, Jinca C, Klukowska A, Laguna P, Wolf DM.
    Haemophilia; 2012 Mar 01; 18(2):175-81. PubMed ID: 21812863
    [Abstract] [Full Text] [Related]

  • 38. Thrombogenicity of a factor IX concentrate quantitated in a canine model.
    MacGregor IR, Ferguson JF, Dawes J, McLaughlin L, Prowse CV.
    Blood Coagul Fibrinolysis; 1990 Mar 01; 1(1):23-30. PubMed ID: 2102787
    [Abstract] [Full Text] [Related]

  • 39. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E, Mannucci PM, Gringeri A, Tagariello G, Baudo F, Bauer KA, Rosenberg RD.
    Thromb Haemost; 1994 Jun 01; 71(6):737-40. PubMed ID: 7974341
    [Abstract] [Full Text] [Related]

  • 40. Properties of factor IX concentrates.
    Berntorp E.
    Acta Haematol; 1995 Jun 01; 94 Suppl 1():8-11. PubMed ID: 7571997
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.